| Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance SY Ku, S Rosario, Y Wang, P Mu, M Seshadri, ZW Goodrich, ... Science 355 (6320), 78-83, 2017 | 895 | 2017 |
| SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ... Science 355 (6320), 84-88, 2017 | 881 | 2017 |
| Genetic dissection of the miR-17∼ 92 cluster of microRNAs in Myc-induced B-cell lymphomas P Mu, YC Han, D Betel, E Yao, M Squatrito, P Ogrodowski, ... Genes & development 23 (24), 2806-2811, 2009 | 589 | 2009 |
| Widespread regulatory activity of vertebrate microRNA* species JS Yang, MD Phillips, D Betel, P Mu, A Ventura, AC Siepel, KC Chen, ... Rna 17 (2), 312-326, 2011 | 466 | 2011 |
| Targeting breast cancer metastasis X Jin, P Mu Breast cancer: basic and clinical research 9, BCBCR. S25460, 2015 | 290 | 2015 |
| Intact p53-dependent responses in miR-34–deficient mice CP Concepcion, YC Han, P Mu, C Bonetti, E Yao, A D'andrea, JA Vidigal, ... PLoS genetics 8 (7), e1002797, 2012 | 227 | 2012 |
| Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer Z Zhang, WR Karthaus, YS Lee, VR Gao, C Wu, JW Russo, M Liu, ... Cancer Cell 38 (2), 279-296. e9, 2020 | 166 | 2020 |
| An allelic series of miR-17∼ 92–mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron YC Han, JA Vidigal, P Mu, E Yao, I Singh, AJ González, CP Concepcion, ... Nature genetics 47 (7), 766-775, 2015 | 118 | 2015 |
| Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation Z Zhang, C Zhou, X Li, SD Barnes, S Deng, E Hoover, CC Chen, YS Lee, ... Cancer cell 37 (4), 584-598. e11, 2020 | 107 | 2020 |
| The paracrine induction of prostate cancer progression by caveolin-1 CJ Lin, EJ Yun, UG Lo, YL Tai, S Deng, E Hernandez, A Dang, YA Chen, ... Cell Death & Disease 10 (11), 834, 2019 | 48 | 2019 |
| Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, A Mukherji, U Lo, L Xu, ... Nature cancer 3 (9), 1071-1087, 2022 | 44 | 2022 |
| SOX2 mediates metabolic reprogramming of prostate cancer cells L de Wet, A Williams, M Gillard, S Kregel, S Lamperis, LC Gutgesell, ... Oncogene 41 (8), 1190-1202, 2022 | 26 | 2022 |
| Valproic acid sodium inhibits the morphine-induced conditioned place preference in the central nervous system of rats P Mu, LC Yu Neuroscience letters 426 (3), 135-138, 2007 | 21 | 2007 |
| Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer X Li, Y Wang, S Deng, G Zhu, C Wang, NA Johnson, Z Zhang, CR Tirado, ... Cancer cell 41 (8), 1427-1449. e12, 2023 | 10 | 2023 |
| The driver role of JAK‐STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy‐and castration‐resistant prostate cancer UG Lo, YA Chen, J Cen, S Deng, J Luo, H Zhau, L Ho, CH Lai, P Mu, ... Clinical and Translational Medicine 12 (8), e978, 2022 | 10 | 2022 |
| MicroRNAs in Prostate Cancer: Small RNAs with Big Roles P Mu, S Deng, X Fan J Clin Cell Immunol 6 (2), 2015 | 5 | 2015 |
| Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview EB Blatt, N Kopplin, S Kumar, P Mu, SD Conzen, GV Raj Endocrine-related cancer 28 (2), R31-R46, 2021 | 4 | 2021 |
| UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance C Rodriguez Tirado, C Wang, X Li, S Deng, J Gonzalez, NA Johnson, ... Oncogene 43 (4), 265-280, 2024 | 1 | 2024 |
| The critical interplay of CAF plasticity and resistance in prostate cancer X Li, P Mu Cancer research 83 (18), 2990-2992, 2023 | 1 | 2023 |
| Abstract PO-117: CHD1-loss promotes tumor heterogeneity and therapy resistance in prostate cancer Z Zhang, C Zhou, X Li, C Sawyers, P Mu Cancer Research 80 (21_Supplement), PO-117-PO-117, 2020 | 1 | 2020 |
Andrea VenturaMember, MSKCCEmail verificata su mskcc.org
